PATENT CLAIM ANALYSIS

Application Number: 16074579
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["424", "452000"]

Abstract:
The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Claim (Index 12):
The minitablet according to  claim 11 , wherein said film-coating comprises the basic butylated methacrylate copolymer in an amount of 50% to 70% by weight, talcum in an amount of 20% to 40% by weight, stearic acid or Mg 5tearate in an amount of 5% to 10% by weight, sodium lauryl sulphate in an amount of 4% to 8% by weight.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 96.0
- Lexical Diversity: 1.53623
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15755733', '15568550', '16046531', '15735717', '16060297']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7027903893411106
- 35 USC 102 Novelty (BERT): 0.5241782736208588
- Combined Prediction Score: 0.6849291777690855
- Mean Citation Score: 229.49906
- Max Citation Score: 275.04184
- Similarity Product: 168.08005702778811

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test